This article is more than 5 years old. Information may no longer be current.

VIDEO: Study examines pembrolizumab in combination with ipilimumab or interferon for melanoma, renal cell carcinoma

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

In this video, Michael B. Atkins, MD, of Georgetown University School of Medicine and the Georgetown-Lombardi Comprehensive Cancer Center in Washington, DC, reviews the results of the phase 1 study he presented at ASCO that studied pembrolizumab plus ipilimumab or pegylated interferon alfa-2b for advanced melanoma or renal cell carcinoma.

Atkins describes the study design, which was conducted “to try to determine what the optimal dose was for further expansion,” and the results. In the pembrolizumab (Keytruda, Merck) plus ipilimumab (Yervoy, Bristol-Myers Squibb) arm, a “fair amount of activity” was observed, including 2 complete responses among patients with melanoma and 3 partial responses among patients with kidney cancer. In patients treated with pembrolizumab plus interferon, there was “some activity” in melanoma, but “very little activity” in kidney cancer.

The pembrolizumab combination has moved into an expansion cohort among patients with melanoma, but the pegylated interferon combination was not advanced into further studies, according to Atkins.